{{Cite journal| doi = 10.1136/bmjopen-2024-084825| issn = 2044-6055 (Electronic) 2044-6055 (Linking)| volume = 14| issue = 11| pages = –084825| last1 = Stirnemann| first1 = J.| last2 = Serratrice| first2 = J.| last3 = Mann| first3 = T.| last4 = Louge| first4 = P.| last5 = Christophe| first5 = C.| last6 = Samii| first6 = K.| last7 = Pignel| first7 = R.| last8 = Agoritsas| first8 = T.| last9 = Ansari| first9 = M.| last10 = Cannas| first10 = G.| last11 = Chalandon| first11 = Y.| last12 = Cimasoni| first12 = L.| last13 = Cougoul| first13 = P.| last14 = Desgraz| first14 = B.| last15 = Gervaix| first15 = A.| last16 = Grosgurin| first16 = O.| last17 = Joffre| first17 = T.| last18 = Lae| first18 = C.| last19 = Magnan| first19 = M. A.| last20 = Menager| first20 = E.| last21 = Momo Bona| first21 = A.| last22 = Panchard| first22 = M. A.| last23 = Pellegrini| first23 = M.| last24 = Reny| first24 = J. L.| last25 = Riu| first25 = B.| last26 = Sahyoun| first26 = C.| last27 = Boet| first27 = S.| title = Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study)| journal = BMJ Open| date = 2024-11-30| pmid = 39613437}}